Which condition must be monitored for patients receiving HMG coenzyme A reductase inhibitors?

Patients receiving HMG coenzyme A reductase inhibitors, commonly known as statins, require close monitoring of liver function due to the potential impact these medications can have on liver health. Statins are metabolized by the liver, and there is a risk of hepatotoxicity, which can manifest as elevated liver enzyme levels. Regular blood tests to check levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) become important to ensure that the liver is functioning properly and to detect any signs of liver damage early.

While kidney function, blood pressure, and blood sugar may also be relevant health considerations in patients taking statins, the direct association with liver function monitoring makes it the primary focus in this context. Statins, while beneficial for lowering cholesterol levels and reducing cardiovascular risks, require caution regarding their effects on the liver, leading to the necessity of monitoring liver enzymes during treatment.